Skip to main content
NCBI home page
Heart logoLink to Heart
. 1998 Aug;80(2):151–155. doi: 10.1136/hrt.80.2.151

Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension

T Higenbottam 1, A Butt 1, A McMahon 1, R Westerbeck 1, L Sharples 1
PMCID: PMC1728783  PMID: 9813561

Abstract

Objective—To investigate the relation between the severity of pulmonary hypertension and the outcome of medical treatment.
Methods—98 patients with primary pulmonary hypertension—nine (6%) with systemic disease and pulmonary hypertension and 39 (27%) with thromboembolic pulmonary hypertension—received medical treatment and were followed between 1982 and 1995. They were given long term intravenous prostaglandin treatment (either epoprostenol (n = 61) or iloprost (n = 13)) or conventional treatment with oral anticoagulants (n = 24) with or without calcium channel blockers. Event-free survival was measured to death or transplant surgery, or pulmonary thromboendarterectomy.
Results—Prognosis (hazard ratio) was affected by: New York Heart Association grade, 1.52 (95% confidence interval 1.11 to 2.09); mixed venous oxygen saturation (SvO2%), 0.97 (0.95 to 0.98); cardiac index, 0.72 (0.49 to 1.06); mean right atrial pressure, 1.04 (1.01 to 1.07); and pulmonary vascular resistance, 1.02 (1.00 to 1.04). The median event-free survival time of patients with SvO2 < 60% was 239 days (0 to 502) on conventional treatment (n = 22) and 585 days (300 to 870) on prostaglandin treatment (n = 42). No difference was seen in patients with SvO2 ⩾ 60% between conventional treatment and prostaglandin treatment, survival being 1275 days (732 to 1818; (n = 48)) and 986 days (541 to 1431; n = 30)), respectively. Capacity for pulmonary vasodilatation did not predict outcome of treatment.
Conclusions—Continuous intravenous prostaglandins were more effective than anticoagulants, with or without calcium channel blockers, in prolonging survival in patients with right heart failure. In these patients a capacity to vasodilate did not predict outcome from medical treatment.

 Keywords: prostacyclin;  iloprost;  pulmonary hypertension;  event-free survival

Full Text

The Full Text of this article is available as a PDF (94.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29;335(9):609–616. doi: 10.1056/NEJM199608293350901. [DOI] [PubMed] [Google Scholar]
  2. Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296–301. doi: 10.1056/NEJM199602013340504. [DOI] [PubMed] [Google Scholar]
  3. D'Alonzo G. E., Barst R. J., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Kernis J. T. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 Sep 1;115(5):343–349. doi: 10.7326/0003-4819-115-5-343. [DOI] [PubMed] [Google Scholar]
  4. Dawkins K. D., Jamieson S. W., Hunt S. A., Baldwin J. C., Burke C. M., Morris A., Billingham M. E., Theodore J., Oyer P. E., Stinson E. B. Long-term results, hemodynamics, and complications after combined heart and lung transplantation. Circulation. 1985 May;71(5):919–926. doi: 10.1161/01.cir.71.5.919. [DOI] [PubMed] [Google Scholar]
  5. Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 Oct;70(4):580–587. doi: 10.1161/01.cir.70.4.580. [DOI] [PubMed] [Google Scholar]
  6. Higenbottam T. W., Butt A. Y., Dinh-Xaun A. T., Takao M., Cremona G., Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998 Feb;79(2):175–179. doi: 10.1136/hrt.79.2.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Higenbottam T. W., Spiegelhalter D., Scott J. P., Fuster V., Dinh-Xuan A. T., Caine N., Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993 Oct;70(4):366–370. doi: 10.1136/hrt.70.4.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Higenbottam T., Wheeldon D., Wells F., Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984 May 12;1(8385):1046–1047. doi: 10.1016/s0140-6736(84)91452-1. [DOI] [PubMed] [Google Scholar]
  9. Hopkins W. E., Ochoa L. L., Richardson G. W., Trulock E. P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):100–105. [PubMed] [Google Scholar]
  10. Hosenpud J. D., Novick R. J., Bennett L. E., Keck B. M., Fiol B., Daily O. P. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report--1996. J Heart Lung Transplant. 1996 Jul;15(7):655–674. [PubMed] [Google Scholar]
  11. Jones D. K., Higenbottam T. W., Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J. 1987 Mar;57(3):270–278. doi: 10.1136/hrt.57.3.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McGavin C. R., Gupta S. P., McHardy G. J. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J. 1976 Apr 3;1(6013):822–823. doi: 10.1136/bmj.1.6013.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moser K. M., Auger W. R., Fedullo P. F., Jamieson S. W. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J. 1992 Mar;5(3):334–342. [PubMed] [Google Scholar]
  14. Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]
  15. Stein P. D., Hull R. D., Saltzman H. A., Pineo G. Strategy for diagnosis of patients with suspected acute pulmonary embolism. Chest. 1993 May;103(5):1553–1559. doi: 10.1378/chest.103.5.1553. [DOI] [PubMed] [Google Scholar]
  16. de la Mata J., Gomez-Sanchez M. A., Aranzana M., Gomez-Reino J. J. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum. 1994 Oct;37(10):1528–1533. doi: 10.1002/art.1780371018. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES